Insider Transactions in Q2 2024 at Biomarin Pharmaceutical Inc (BMRN)
Insider Transaction List (Q2 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 28
2024
|
Brian Mueller EVP, Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
588
-0.81%
|
$48,216
$82.33 P/Share
|
|
Jun 03
2024
|
Elaine J Heron Director |
SELL
Payment of exercise price or tax liability
|
Direct |
4,168
-4.09%
|
$316,768
$76.41 P/Share
|
|
Jun 03
2024
|
Elaine J Heron Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,047
+4.72%
|
$317,961
$63.1 P/Share
|
|
Jun 03
2024
|
Richard A Meier Director |
SELL
Payment of exercise price or tax liability
|
Direct |
5,451
-4.32%
|
$414,276
$76.41 P/Share
|
|
Jun 03
2024
|
Richard A Meier Director |
BUY
Exercise of conversion of derivative security
|
Direct |
6,600
+4.97%
|
$415,800
$63.1 P/Share
|
|
May 30
2024
|
Brian Mueller EVP, Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
5,000
-6.48%
|
$375,000
$75.19 P/Share
|
|
May 30
2024
|
Brian Mueller EVP, Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+6.09%
|
$315,000
$63.1 P/Share
|
|
May 28
2024
|
George Eric Davis EVP, Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
40,850
-21.98%
|
$3,022,900
$74.87 P/Share
|
|
May 28
2024
|
George Eric Davis EVP, Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
40,850
+29.63%
|
$2,573,550
$63.1 P/Share
|
|
May 21
2024
|
Richard A Meier Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,080
+5.59%
|
-
|
|
May 21
2024
|
David E I Pyott Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,720
+8.67%
|
-
|
|
May 21
2024
|
Maykin Ho Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,720
+18.1%
|
-
|
|
May 21
2024
|
Robert J. Hombach Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,720
+11.82%
|
-
|
|
May 21
2024
|
Elaine J Heron Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,720
+4.65%
|
-
|
|
May 21
2024
|
Willard H Dere Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,720
+12.75%
|
-
|
|
May 21
2024
|
Mark J Enyedy Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,720
+40.62%
|
-
|
|
May 21
2024
|
Athena Countouriotis Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,720
+40.62%
|
-
|
|
May 21
2024
|
Elizabeth M Anderson Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,720
+14.51%
|
-
|
|
May 21
2024
|
Barbara W. Bodem Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,720
+40.62%
|
-
|
|
May 20
2024
|
Cristin Hubbard EVP, Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
19,390
+34.76%
|
-
|
|
May 20
2024
|
Jean Jacques Bienaime Director |
SELL
Payment of exercise price or tax liability
|
Direct |
1,202
-0.25%
|
$92,554
$77.05 P/Share
|
|
May 17
2024
|
Erin Burkhart GVP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
993
-6.15%
|
$75,468
$76.97 P/Share
|
|
May 10
2024
|
Jean Jacques Bienaime Director |
SELL
Open market or private sale
|
Direct |
20,000
-4.04%
|
$1,620,000
$81.14 P/Share
|
|
May 10
2024
|
Jean Jacques Bienaime Director |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+3.88%
|
$1,260,000
$63.1 P/Share
|
|
May 09
2024
|
Jean Jacques Bienaime Director |
SELL
Open market or private sale
|
Direct |
20,000
-4.04%
|
$1,620,000
$81.62 P/Share
|
|
May 09
2024
|
Jean Jacques Bienaime Director |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+3.88%
|
$1,260,000
$63.1 P/Share
|
|
May 03
2024
|
Charles Greg Guyer EVP, Chief Technical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,440
-5.65%
|
$364,080
$82.44 P/Share
|
|
May 02
2024
|
George Eric Davis EVP, Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
1,850
-3.19%
|
$157,250
$85.01 P/Share
|
|
May 02
2024
|
George Eric Davis EVP, Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,850
+3.09%
|
$116,550
$63.1 P/Share
|
|
May 02
2024
|
Jeffrey Robert Ajer EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
5,000
-6.97%
|
$410,000
$82.91 P/Share
|
|
Apr 30
2024
|
Henry J Fuchs President, Worldwide R&D |
BUY
Grant, award, or other acquisition
|
Direct |
300
+0.15%
|
$20,400
$68.65 P/Share
|
|
Apr 30
2024
|
Brian Mueller EVP, Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
300
+0.41%
|
$20,400
$68.65 P/Share
|
|
Apr 30
2024
|
Charles Greg Guyer EVP, Chief Technical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
245
+0.31%
|
$16,660
$68.65 P/Share
|
|
Apr 30
2024
|
George Eric Davis EVP, Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
301
+0.53%
|
$20,468
$68.65 P/Share
|
|
Apr 30
2024
|
Jeffrey Robert Ajer EVP, Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
300
+0.42%
|
$20,400
$68.65 P/Share
|
|
Apr 12
2024
|
Jean Jacques Bienaime Director |
SELL
Open market or private sale
|
Direct |
20,000
-4.04%
|
$1,820,000
$91.26 P/Share
|
|
Apr 12
2024
|
Jean Jacques Bienaime Director |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+3.88%
|
$1,260,000
$63.1 P/Share
|
|
Apr 11
2024
|
Jean Jacques Bienaime Director |
SELL
Open market or private sale
|
Direct |
20,000
-4.04%
|
$1,800,000
$90.99 P/Share
|
|
Apr 11
2024
|
Jean Jacques Bienaime Director |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+3.88%
|
$1,260,000
$63.1 P/Share
|
|
Apr 10
2024
|
Erin Burkhart GVP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
2,286
-12.4%
|
$205,740
$90.0 P/Share
|